1258 related articles for article (PubMed ID: 11818462)
1. Cyclooxygenase-2: a therapeutic target.
Turini ME; DuBois RN
Annu Rev Med; 2002; 53():35-57. PubMed ID: 11818462
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
van der Bijl P; van der Bijl P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
[TBL] [Abstract][Full Text] [Related]
3. [Coxibs: cyclooxygenase-2 inhibitors].
Turnheim K
Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
[TBL] [Abstract][Full Text] [Related]
4. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors.
Buttar NS; Wang KK
Mayo Clin Proc; 2000 Oct; 75(10):1027-38. PubMed ID: 11040851
[TBL] [Abstract][Full Text] [Related]
5. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
6. Potential role of selective COX-2 inhibitors in cancer management.
Dang CT; Shapiro CL; Hudis CA
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):30-6. PubMed ID: 12102578
[TBL] [Abstract][Full Text] [Related]
7. [Clinical application of cyclooxygenase-2 inhibitors].
Dzielska-Olczak M; Olczak S
Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
[TBL] [Abstract][Full Text] [Related]
8. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications.
Pascucci RA
J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 inhibitors: promise or peril?
Mengle-Gaw LJ; Schwartz BD
Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
[TBL] [Abstract][Full Text] [Related]
10. [Current status of study on selective cyclooxygenase-2 inhibitors and evaluation of its application].
He W; Liu CF; Huang CQ
Di Yi Jun Yi Da Xue Xue Bao; 2002 Feb; 22(2):184-6. PubMed ID: 12390825
[TBL] [Abstract][Full Text] [Related]
11. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
Howard PA; Delafontaine P
J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
[TBL] [Abstract][Full Text] [Related]
12. [Non-steroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors].
Miehle W
Wien Med Wochenschr; 1999; 149(19-20):541-5. PubMed ID: 10637962
[TBL] [Abstract][Full Text] [Related]
13. [New nonsteroidal antirheumatic drugs].
Forster A; Michel BA
Praxis (Bern 1994); 2000 May; 89(20):855-60. PubMed ID: 10865508
[No Abstract] [Full Text] [Related]
14. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
15. [COX-2 inhibitor to whom?].
Martio J
Duodecim; 2000; 116(12):1265-7. PubMed ID: 11988961
[No Abstract] [Full Text] [Related]
16. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Atkinson HG
Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
[No Abstract] [Full Text] [Related]
17. [A new class of nonsteroidal anti-inflammatory agents: COXIBs].
Costantino S
Clin Ter; 2003; 154(1):5-6. PubMed ID: 12854276
[No Abstract] [Full Text] [Related]
18. Aspirin and NSAID sensitivity.
Stevenson DD
Immunol Allergy Clin North Am; 2004 Aug; 24(3):491-505, vii. PubMed ID: 15242723
[TBL] [Abstract][Full Text] [Related]
19. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
Hinz B; Brune K
Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
[TBL] [Abstract][Full Text] [Related]
20. [Safe use of anti-inflammatory analgesics].
Finnish Society of Gastroenterology and the Task force of Finnish Rheumatological Society
Duodecim; 2003; 119(22):2167-71. PubMed ID: 14702803
[No Abstract] [Full Text] [Related]
[Next] [New Search]
